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Abstract
Purpose Chemotherapy-induced alopecia (CIA) is a stigmatizing and psychologically devasting side effect of cancer treatment. Scalp cooling therapy (SCT) is the most effective method to reduce CIA, yet it is underutilized. We investigated factors
that may impact scalp cooling discussion and use.
Methods We performed a retrospective review of cancer patients from 2000 to 2019 who had documentation of SCT discussion in the electronic medical record. The University of Michigan Rogel Cancer Center registry was used to identify
the total number of cancer patients eligible for SCT during 2015–2019. Chi-square tests were used for outcome and patient
characteristic comparisons (p < 0.05).
Results From 2000 to 2019, 194 patients had documentation of SCT discussion. Of those, 72 (43.6%) used SCT, 93 (47.9%)
did not use SCT, and the remaining 29 (17.8%) had unknown SCT use. A total of 5615 cancer patients were eligible for SCT
from 2015 to 2019. As compared to those who did not have documented SCT discussions, patients who had documentation
of SCT discussions in that period (n = 161, 3.0%) were more likely to be female, have breast cancer, be less than 45 years
old, and live in a zip code with average income > US $100,000 (all p < 0.0001). Between 2015 and 2019, 57 patients (1.02%)
used SCT. On univariate analysis, patient-initiated conversation about SCT (p = 0.01) and age less than 65 (p = 0.03) were
significantly associated with decision to use SCT.
Conclusion There were distinctions in the types of patients who have documented discussions about SCT. Improving patient
knowledge about the availability of SCT and increasing access to this technology for all eligible cancer patients may enable
more patients to achieve improved quality of life by reducing or preventing CIA.
Keywords Scalp cooling therapy · Chemotherapy-induced alopecia · Cold cap therapy · Hair loss prevention · Manual cold
caps
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Chemotherapy-induced alopecia (CIA) is a highly stigmatized and psychologically devasting side effect of cancer
treatment [1]. Scalp cooling systems are the most effective,
FDA-cleared method identified to date for reducing CIA,
with data from clinical trials supporting their efficacy [2].
However, most hospitals only permit manual cold cap use,
which requires patients to privately rent the caps and bring
their own equipment to the hospital for use.
Currently, there is a difference in the options hospitals
offer patients with regard to scalp cooling therapy (SCT),
and there are notable barriers for patients to access centers with scalp cooling [3, 4]. Various other factors have
been postulated to impact patient use of SCT, including
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awareness, provider support, and effort involved in addition
to financial, efficacy, and safety concerns [3, 5–8].
While it is widely known that SCT use is low in the USA,
especially when compared to European counterparts, little
data exist about the overall use of SCT at specific centers,
and which factors impact SCT use [1, 3, 5, 9–11]. To further
understand the landscape of patient SCT use, we present
a single-center retrospective study of scalp cooling implementation at an academic institution that permits manual
cold caps.

who underwent chemotherapy. The analysis of this group
was limited to years 2015 to 2019. Due to limitations in the
data available from the registry, chemotherapy setting and
chemotherapy type for the entire population could not be
included in this analysis.
Descriptive statistics were used to report baseline patient
characteristics. Chi-square tests were used for outcome and
patient characteristic comparisons. P-values of < 0.05 were
considered statistically significant. This study was approved
by the University of Michigan Institutional Review Board.

Methods

Results

We conducted a retrospective cohort study of University
of Michigan Rogel Cancer Center patients who have documentation of SCT discussion in the electronic health record
(EHR) between January 2000 and December 2019. During
this period, the SCT option offered to patients at this institution was use of manual cold caps with patient-supplied dry
ice. EMERSE, a medical record search engine, was used to
identify University of Michigan charts with the following
key words: “cold caps,” “cold cap,” “scalp cooling,” “Paxman Scalp Cooling,” “Dignicaps,” “Dignicap,” “Paxman,”
“Penguin,” “scalp hypothermia,” “ice cap,” and “ice caps”
[12]. Further chart review was conducted to identify patients
with documentation of SCT discussion for inclusion in this
study.
Demographic, disease characteristics, and cancer treatment information was collected on the subset of patients
for whom SCT discussion was documented. Each chart was
reviewed to determine who initiated the SCT conversation
(patient, provider, or unclear) and if the patient used SCT
(yes, no, unknown). Efficacy and side effects of SCT and
the medical management of side effects were also noted for
those who used SCT. Scalp cooling was considered effective when the note stated that the patient was “satisfied” (or
similar words that indicated satisfaction) with their result
or when the provider noted that there was “little to no hair
loss.” If efficacy was not clearly noted, then this was charted
as “unclear.” Data were collected and corroborated by 2
independent reviewers (TN, MN).
Characteristics of cancer patients who decided to use SCT
were compared to those who opted out. Cancer patients who
did not have a clearly documented decision about SCT use
or did not undergo chemotherapy were excluded from this
analysis.
Demographic and disease specific information of cancer
patients with documentation of SCT discussion were compared to those without documentation among the general
cancer patient population eligible for SCT in the University of Michigan Rogel Cancer Center Registry. Eligibility
for SCT was defined as patients with solid tumor cancers

From 2000 to 2019, 194 patients had documentation of SCT
discussion in the EHR (Table 1). Most of the documented
discussions (161/194, 83%) occurred after 2015. Thirty
received chemotherapy at another institution, of which seven
patients were documented as having received chemotherapy
elsewhere due to lack of support for cold caps (e.g., no freezers for manual caps, no machine system).
During 2015–2019, 5615 cancer patients were identified
who were eligible for SCT use at the study center, of which
161 patients (2.9%) had documented SCT discussions during
this period and 57 patients (1.02%) were identified as having
used SCT. As compared to the patients who did not have
documentation of SCT discussions (n = 5454), those with
documentation of SCT discussions (3.0%) were more likely
to be female, have breast cancer, be less than 45 years old,
and live in a zip code with average income > US $100,000
(all p < 0.0001) (Table 2). In addition, of those with documented SCT discussions, 82% were white and 9% Black, as
compared to 90% and 5% in the population without documented SCT discussions (p = 0.01) (Table 2).
From 2000 to 2019, 165 (165/194, 86.6%) patients had
clear documentation in the EHR of a SCT decision (Table 1).
Of those, 72 (43.6%) chose to use SCT, while 93 (56.4%) did
not choose this option. Patients 65 years old or younger were
significantly more likely to use SCT than those older than
65 years of age (p = 0.03). Forty-eight percent of patients
who initiated the conversation about SCT with their providers used SCT whereas only 9.6% of patients used SCT if the
provider initiated the discussion (p = 0.01). No significant
associations were identified between the decision to use SCT
and type of cancer, average zip code income, living in a
metropolitan versus non-metropolitan area, adjuvant (stage
1–3) versus palliative (stage 4) therapy, year of diagnosis,
and undergoing anthracycline vs. non-anthracycline chemotherapy (Fig. 1).
Of the 37 patients for whom SCT efficacy could be clearly
identified from the EHR, 26 (70.2%) had effective SCT. Side
effects included “discomfort,” nausea/vomiting, pain, and
headaches. No serious adverse events were noted.
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Table 1  Characteristics of all cancer patients with documented clinical discussions of SCT from 2000 to 2019
All cancer patients with documented clinical
discussions of SCT (n = 194) (n, %)
Gender
Male

4 (2.1)

Female

190 (98.0)

Race
White

163 (84.0)

Black

15 (7.7)

Other

16 (8.2)

Type of cancer
Breast cancer

154 (79.4)

Gynecologic

17 (8.8)

Lymphoma

8 (4.1)

Gastrointestinal

5 (2.6)

Genitourinary

2 (1.0)

Lung

2 (1.0)

Other

6 (3.1)

Age
< 45

55 (28.4)

45–65

104 (53.6)

> 65

35 (18.0)

Zip code average income
< $100 k

110 (56.7)

> $100 k

74 (38.1)

Out of state

10 (5.2)

Zip code metro/non-metro
Metro

114 (58.8)

Non-metro

70 (36.1)

Out of state

10 (5.2)

Chemotherapy setting
Adjuvant

155 (80.0)

Palliative

32 (16.5)

No chemo

7 (3.6)

Chemotherapy type
Anthracycline
Non-anthracycline
Uncleara

53 (27.3)
120 (61.9)
21 (10.8)

Date of chemotherapy
< 2010

4 (2.1)

2010–2015

29 (15.0)

2015 +

161 (83.0)

Decision to use
Used SCT

72 (37.1)

Did not use SCT

93 (47.9)

No chemotherapy

7 (3.6)

Unclear

22 (11.3)

Initiation of conversation

a

Patient

54 (27.8)

Provider

78 (40.2)

Unclear

62 (32.0)

Patients did not receive chemotherapy infusion at our institution and
no clear documentation of what they received

Discussion
This is a single center retrospective study of scalp cooling
practices at a large academic center that permits manual cold
capping. In this study, a distinction was identified in the
type of patients who were more likely to have documented
discussions about SCT, which included younger, female
breast cancer patients living in higher income areas. Our
data also shows that a very small proportion of patients used
SCT. Age (≤ 65 years old) and patient-initiated discussion
about SCT were the significant factors found that positively
impacted patient decisions to use SCT.
We identified a very narrow and specific patient population (female, breast cancer patients) that had documented
discussions about SCT. To our knowledge, this is the first
study to examine the characteristics of cancer patients
offered SCT. However, we also found that most patients
who used SCT at our institution were female, younger, and
breast cancer patients. These findings are consistent with
previously reported data on the landscape of SCT use and
may be due to targeted offerings of SCT. In a 2012 Dutch
registry study of 1411 chemotherapy patients who used SCT,
96% were women and 86% had breast cancer [13]. Both of
the landmark clinical trials in the USA in 2017 also only
reported on female, breast cancer patients [14, 15]. Recent
data on the use of Paxman machines from 2017 to 2020 at
major centers across the USA noted that 78% of patient users
had breast cancer followed by 12% with gynecologic tumors,
which parallels our data [9]. As a result of the expanded
FDA clearance of SCT for all solid tumor cancers in 2017,
all such patients should routinely be offered this technology,
coupled with further studies on a broader group of cancer
patients to assess efficacy with different factors including
chemotherapy regimens. Furthermore, many male patients
can also benefit from prevention of CIA, although they are
infrequently offered and/or use SCT [16–18].
In addition to being female and having breast cancer,
we found increased rates of documented SCT discussions
with younger patients. Younger patients seeking privacy
at work and who have young children may be more motivated to use SCT [8]. However, patients with a wide range
of ages have been found to use and benefit from scalp
cooling. In a 2018 registry study of cold cap use at the
University of California-San Francisco, the median age
of SCT use was 48, with a range from 27 to 83 years. In
the Netherland Registry study, only 21% of patients were
less than 45 years old [19]. The majority of patients using
scalp cooling systems at major institutions across the USA
were between the ages of 45–65 (55%), followed by 65–74
(18%), older than 75 (5%), and 25–44 (2%) [9]. Additional
research with a larger sample size is needed to further
investigate the impact of age on the decision to use SCT.
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Table 2  Cancer patients with
documented discussions of
SCT compared to those without
documented SCT discussions
among total University of
Michigan Cancer Center
patient population eligible for
SCT from 2015 to 2019 in a
univariate analysis

Gender
Male
Female
Race
White
Black
Other/unknown
Type of cancer
Breast cancer
Otherb
Age
< 45
45–65
> 65
Zip code average income
< $100 k
> $100 k
Out of state
Metro/non-metro
Metro
Non-metro
Out of state

Documented SCT discussions
(n = 161) (n, %)

No documented SCT discussions
(n = 5,454)a (n, %)

p-value

2 (1)
159 (99)

2,464 (45)
2,990 (55)

< 0.0001

132 (82)
14 (9)
15 (9.3)

4,889 (90)
265 (5)
300 (5.5)

0.008

131 (81)
30 (19)

1,023 (19)
4,431 (81)

< 0.0001

45 (28)
87 (54)
29 (18)

555 (10)
2,925 (54)
1,973 (36)

< 0.0001

92 (57)
60 (37)
9 (6)

4,248 (78)
883 (16)
323 (6)

< 0.0001

94 (58)
58 (36)
9 (6)

2,673 (49)
2,458 (45)
323 (6)

0.06

a

5615 cancer patients were identified who were eligible for SCT use at the study center from 2015 to 2019,
of whom 5454 did not have documentation of SCT discussion and/or use. Eligible patients were defined as
patients with solid tumor cancers undergoing chemotherapy

b

Other cancers include gynecologic (15), lymphoma (5), gastrointestinal (GI) (4), lung (2), genitourinary
(1), and other (3)

SCT is not generally covered by insurance and can be
costly (approximately US $300–$500 per month of use). In
a national survey of oncologists, the number one providerreported reason for not discussing SCT with patients was
financial concerns [5]. Although this cost may be prohibitive
for many patients, we did not find a statistically significant
difference in the use of SCT between patients who lived in
higher versus lower income zip codes. While income by zip
code may not serve as a fully accurate proxy for financial
capacity, financial support programs (e.g., Hair to Stay, Cold
Capital Fund, Cap & Conquer) and increased reimbursement
with specific ICD and CPT codes (e.g., Z51.11, L65.9 &
A9273, A9282) may increase access to SCT for patients of
lower socioeconomic status. [20, 21]. Therefore, providers
should not limit discussions based on presumed financial
status [5]. Given the psychosocial distress of chemotherapy induced alopecia and SCT’s proven efficacy for many
patients, widespread insurance coverage would be ideal for
all affected patients.
We also found that there was no difference between using
or not using SCT based on the goal of chemotherapy (palliative versus curative), although given the small numbers
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in our study this finding may be due to insufficient statistical power. Most SCT studies have focused principally on
patients undergoing chemotherapy with curative intent [14,
22, 23]. Our results support discussing SCT with patients
undergoing palliative chemotherapy as well.
Overall, a very small proportion of the patients at our
large academic cancer center have documentation of
discussing SCT from 2000 to 2019 (194 patients), with
1% of the eligible cancer patient using SCT from 2015
onward. The low discussion and usage rate is consistent
with prior research noting the lack of availability and use
of SCT, particularly in the USA [3, 4, 6, 8]. This may in
part be due to lack of clinic protocols or known narrative language to educate patients about SCT. In a recent
study, while the majority of providers were in favor of
SCT, only 25% of oncology providers surveyed answered
that they consistently initiated conversations with patients
about SCT [5]. Similar to oncofertility programs that have
increased education and provided clinical narratives to
help providers discuss implementation of fertility preservation, it will be important to establish protocols for
patient education about SCT [24]. The identified low rate
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Fig. 1  Characteristics of cancer patients who decided to use SCT
(gray bars) were compared to those who opted out (black bars) to
determine factors influencing decision to use SCT. Patients who were
65 years old and younger (B, p = 0.03) and those who initiated the
SCT conversation with their provider (I, p = 0.01) were significantly

more likely to use SCT. There was no statistically significant difference between patients who used SCT and those who did not based on
gender (A), race (C), classification of zip code (D), average income of
zip code (E), type of cancer (F), chemotherapy setting and (G), and
chemotherapeutic agent (H)

may also be due to omission of documentation in the EMR
about scalp cooling discussions with patients who did not
express interest in using SCT. Further investigation into
additional barriers to patient use of scalp cooling, such as
effort involved, factors that impact efficacy (e.g., capping
technique, chemotherapy regimen, hair care practices), and
possible inconsistent or inaccurate communication about

implementation, will be necessary to increase use of SCT
by appropriate candidates [3].
Limitations to our study relate to the retrospective nature
of this study, which means there may be incomplete or variations in documentation regarding SCT by provider, lack
of objective data regarding SCT efficacy, and inability to
perform CTCAE grading of adverse events. Of note, in our
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center, there were no scalp cooling systems available during
the study dates, which may have influenced the lack of interest by patients and lack of discussion by staff about scalp
cooling. Also, since much of the data regarding the safety
and efficacy of scalp cooling was published later during the
time period covered by our analysis, we may have underestimated the current rates of discussions about and use of SCT
for avoidance of CIA.
In our study, we were able to identify that documented
discussions about and use of SCT were limited and distinctions in the patient population was evident. Offering
information about and access to SCT to all patients who are
initiating chemotherapy for FDA-cleared indications could
positively impact quality of life for patients with cancer
through reducing or preventing CIA.
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